France organoids market accounted for US$ XX Mn in the year 2022 and it is expected to grow at a CAGR of 22.3% during the period 2022 - 2030, to reach US$ XX Mn in the year 2030.
The organoids market growth in France is majorly attributed to the growing funding for research and development activities. Additionally, investments in research and development on cancer, liver diseases, gastrointestinal diseases for organ regeneration, and stem cell research will likely augment the organoids market in Europe during the forecast period. Major companies in the market emphasize establishing new research and development facilities to suffice the extensively growing demand for organoids. For instance, in September 2021, TreeFog Therapeutics, a French innovator, closed funding of US$ 75 million (€64 million) in a Series B financing round. It has gathered a total funding of US$ 83 million (€70 million) to develop affordable stem cell-derived cell therapies. Thus, receiving funds for developing stem cell technologies is likely to propel development of organoids to serve the demand for advanced treatments.
According to the WHO, in 2020, France identified 467,965 new cases, and the number of prevalent cases in 5 years was 1,501,881. The number of cancer cases in the country is expected to rise significantly due to habitual factors. Thus, increasing cancer cases are expected to boost the demand for organoids as a measure for their treatments and help the market to grow in the coming years.
are the key Organoids Market players profiled in the report.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ XX Million |
| Market Size by 2030 | US$ XX Million |
| Global CAGR (2022 - 2030) | 22.3% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Organ Type
|
| Regions and Countries Covered | France
|
| Market leaders and key company profiles |
The List of Companies - Organoids Market